In This Section

Strategies to Assess Drug-Drug Interactions when Developing Fixed Dose Combinations

Tuesday April 09, 2019

8:00 am - 10:00 am Eastern Time (ET)

Room W206 C

CVP DDD DMDD TOX

Chair :

Yurong Lai
Gilead Sciences Inc



Theoretically the drug interaction with a Fixed-Dose Congination can be antagonism, synergism, and potentiation. Therefore, assessing DDI potential for a FDC as a perpetrator practically can be challenge due to complicated mechanisms of interaction. The symposium will be offering the introduction of mechanisms of DDIs involving multiple inhibitors, the methods to assess the total inhibition effects, regulatory guidance on co-development of two or more new investigational drugs for use in combination, in vitro or preclinical data for human prediction and cases examples of DDI assessments to illustrate the strategy when developing FDCs.

Speakers

Polina German - Gilead Sciences, Inc.

Industry Perspectives: DDI Assessment for Fixed Dose Combinations

Nina Isoherranen - University of Washington

Mechanisms of Drug–Drug Interactions Involving Multiple Inhibitors

Chao Liu - The US FDA

Regulatory View on FDC Developments for Oncology and Anti-Infectives

George Drusano - University of Florida

Identifying Optimal Combination Therapy for Mycobacterium Tuberculosis

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019